HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The EXCEL and NOBLE trials: similarities, contrasts and future perspectives for left main revascularisation.

Abstract
Unprotected left main coronary artery (ULMCA) stenosis has relatively high prevalence and exposes patients to a high risk for adverse cardiovascular events. The optimal revascularisation strategy (coronary artery bypass surgery [CABG] or percutaneous coronary intervention [PCI]) for patients with complex coronary artery disease is a topic of continuing debate. The introduction of the newer-generation drug-eluting stents (DES) -with documented improvements in both safety and efficacy- has prompted the interventional community to design two new dedicated randomised trials comparing CABG and PCI: the NOBLE (Coronary Artery Bypass Grafting Vs Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis) and EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trials. The aims of the present review are to describe the similarities and contrasts between these two trials as well to explore their future implications in ULMCA treatment.
AuthorsCarlos M Campos, Evald H Christiansen, Gregg W Stone, Patrick W Serruys
JournalEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (EuroIntervention) Vol. 11 Suppl V Pg. V115-9 ( 2015) ISSN: 1969-6213 [Electronic] France
PMID25983143 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Everolimus
  • umirolimus
  • Sirolimus
Topics
  • Angioplasty, Balloon, Coronary (methods)
  • Antineoplastic Agents (therapeutic use)
  • Coronary Artery Bypass (methods)
  • Coronary Stenosis (therapy)
  • Drug-Eluting Stents
  • Everolimus (therapeutic use)
  • Humans
  • Percutaneous Coronary Intervention (methods)
  • Randomized Controlled Trials as Topic
  • Sirolimus (analogs & derivatives, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: